

Cover Story
Guest Editorial
As the world faced the threat of a novel respiratory pathogen, SARS-CoV-2, in the first months of 2020, there was a great deal of uncertainty about its effect on people, especially those living with a diagnosis of cancer.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Brown University reaches agreement with Trump administration to restore funding
- Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Harvey Risch, critic of COVID-19 response, tapped by White House to serve as chair of the President’s Cancer Panel
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- John Byrd brings blood cancer expertise to solid tumor, immunology powerhouse at UPMC














